Skip to content
10-K

Annual Report

Celldex Therapeutics, Inc. CLDX

0001410578-25-000216

← back to feed
Filed
Feb 27, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 14, 2025 66.38M sh
Cash And Equivalents FY 2024 · Dec 31, 2023 $34.81M
Current Liabilities FY 2024 · Dec 31, 2023 $31.13M
Total Liabilities FY 2024 · Dec 31, 2023 $36.46M
Current Assets FY 2024 · Dec 31, 2023 $431.69M
Total Assets FY 2024 · Dec 31, 2023 $465.63M
Shares Diluted FY 2024 · Dec 31, 2022 46.89K sh
Capex FY 2024 · Dec 31, 2022 $1.83M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$103.73M
Eps Diluted FY 2024 · Dec 31, 2022 −$2.40
Eps Basic FY 2024 · Dec 31, 2022 −$2.40
Sga Expense FY 2024 · Dec 31, 2022 $27.2M
Rd Expense FY 2024 · Dec 31, 2022 $82.26M
Operating Income FY 2024 · Dec 31, 2022 −$115.23M
Cost Of Revenue FY 2024 · Dec 31, 2022 $100K
Revenue FY 2024 · Dec 31, 2022 $2.36M
Stockholders Equity FY 2024 · Dec 31, 2021 $419.48M